I. Stasi

1.6k total citations
25 papers, 1.3k citations indexed

About

I. Stasi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, I. Stasi has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in I. Stasi's work include Colorectal Cancer Treatments and Studies (12 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Treatment and Pharmacology (7 papers). I. Stasi is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Treatment and Pharmacology (7 papers). I. Stasi collaborates with scholars based in Italy and United States. I. Stasi's co-authors include Alfredo Falcone, Fotios Loupakis, Gianluca Masi, Annamaria Ruzzo, Chiara Cremolini, Daniele Santini, Francesco Graziano, Mauro Magnani, Emanuele Canestrari and Giuseppe Tonini and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

I. Stasi

25 papers receiving 1.3k citations

Peers

Countries citing papers authored by I. Stasi

Since Specialization

Citations

This map shows the geographic impact of I. Stasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Stasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Stasi more than expected).

Fields of papers citing papers by I. Stasi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Stasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Stasi. The network helps show where I. Stasi may publish in the future.

Co-authorship network of co-authors of I. Stasi

This figure shows the co-authorship network connecting the top 25 collaborators of I. Stasi. A scholar is included among the top collaborators of I. Stasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Stasi. I. Stasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P17.02.B CORRELATIONS BETWEEN CLINICAL BENEFIT TO SECOND LINE REGIMENS AND NADH-FLIM-BASED DRUG RESPONSE ASSESSMENT MODEL ON RECURRENT GBM PATIENT-DERIVED ORGANOIDS 2023 ·Neuro-Oncology ·Chiara Maria Mazzanti, Mariangela Morelli, Sara Franceschi, Francesca Lessi, Francesco Pieri, Carlo Gambacciani, (unknown), (unknown), Samanta Cupini, I. Stasi, (unknown), Andrea Giusti, (unknown), Orazio Santo Santonocito, (unknown)	1
2	Fronto-mesial-pericallosal gliofibroma 2020 ·Journal of Neurosurgical Sciences ·(unknown), (unknown), Francesco Pieri, (unknown), (unknown), I. Stasi, Orazio Santo Santonocito	2
3	Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 2019 ·Cancer Chemotherapy and Pharmacology ·Stefania Crucitta, Giuliana Restante, Marzia Del Re, Ilaria Bertolini, (unknown), Eleonora Rofi, (unknown), (unknown), Stefano Fogli, I. Stasi, Matteo Ghilli, Andrea Fontana, Romano Danesi	6
4	Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer 2014 ·PubMed ·I. Stasi, Federico Cappuzzo	25
5	Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer 2014 ·SHILAP Revista de lepidopterología ·Federico Cappuzzo, I. Stasi	5
6	Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy. 2012 ·Journal of Clinical Oncology ·Andrea Fontana, Giacomo Allegrini, (unknown), Paola Collecchi, Chiara Maria Mazzanti, I. Stasi, (unknown), (unknown), (unknown), B. Salvadori, (unknown), Lorenzo Marcucci, (unknown), Cinzia Orlandini, Alfredo Falcone, Generoso Bevilacqua, Katia Zavaglia	1
7	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status 2010 ·Critical Reviews in Oncology/Hematology ·Lorenzo Fornaro, Giacomo Giulio Baldi, Gianluca Masi, Giacomo Allegrini, Fotios Loupakis, Enrico Vasile, Samanta Cupini, I. Stasi, Lisa Salvatore, Chiara Cremolini, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Francesco Graziano, Annamaria Ruzzo, Emanuele Canestrari, Mauro Magnani, Alfredo Falcone	19
8	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis 2010 ·JNCI Journal of the National Cancer Institute ·Gianluca Masi, (unknown), Fotios Loupakis, (unknown), Lorenzo Fornaro, Giacomo Giulio Baldi, Lisa Salvatore, Chiara Cremolini, I. Stasi, (unknown), Agnese Fabbri, M. Puglisi, Patrizia Trenta, Cristina Granetto, S. Chiara, Luisa Fioretto, (unknown), Lucio Crinò, M. Andreuccetti, Alfredo Falcone	137
9	Refractory neuroendocrine tumor—response to liposomal doxorubicin and capecitabine 2009 ·Nature Reviews Clinical Oncology ·Gianluca Masi, Lorenzo Fornaro, Samanta Cupini, Fotios Loupakis, Enrico Vasile, Giacomo Giulio Baldi, I. Stasi, Lisa Salvatore, Alfredo Falcone	3
10	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 2009 ·British Journal of Cancer ·Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini, Bruno Vincenzi, Lisa Salvatore, Daniele Santini, Gianluca Masi, I. Stasi, Emanuele Canestrari, Eliana Rulli, Irene Floriani, Katia Bencardino, Nadia Galluccio, Vincenzo Catalano, Giuseppe Tonini, Mauro Magnani, Gabriella Fontanini, Fulvio Basolo, Alfredo Falcone, Francesco Graziano	449
11	Bevacizumab (BV) in combination with folfoxiri (Irinotecan, Oxaliplatin and Infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): a phase II trial by the GONO GROUP 2009 ·CINECA IRIS Institutial research information system (University of Pisa) ·Gianluca Masi, Enrico Vasile, Fotios Loupakis, Lisa Salvatore, Lorenzo Fornaro, Giacomo Giulio Baldi, I. Stasi, Samanta Cupini, A. Ciarlo, Francesca Del Monte, Patrizia Trenta, Silvia Mezi, (unknown), M. Andreuccetti, Alfredo Falcone	2
12	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer 2009 ·Therapeutic Advances in Medical Oncology ·Fotios Loupakis, Chiara Cremolini, Gabriella Fontanini, I. Stasi, Lisa Salvatore, Alfredo Falcone	7
13	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer 2009 ·Journal of Clinical Oncology ·Fotios Loupakis, Luca Emanuele Pollina, I. Stasi, Annamaria Ruzzo, Mario Scartozzi, Daniele Santini, Gianluca Masi, Francesco Graziano, Chiara Cremolini, Eliana Rulli, Emanuele Canestrari, Niccola Funel, Gaia Schiavon, Iacopo Petrini, Mauro Magnani, Giuseppe Tonini, Daniela Campani, Irene Floriani, Stefano Cascinu, Alfredo Falcone	341
14	6060 KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 2009 ·European Journal of Cancer Supplements ·Lisa Salvatore, Fotios Loupakis, Gabriella Fontanini, Chiara Cremolini, I. Stasi, Agnese Fabbri, A. Ciarlo, Cristina Granetto, Fulvio Basolo, Alfredo Falcone	3
15	Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 2009 ·Journal of Clinical Oncology ·Fotios Loupakis, Chiara Cremolini, Gabriele Perrone, I. Stasi, Lisa Salvatore, Bruno Vincenzi, Annamaria Ruzzo, Monica Ronzoni, Katia Bencardino, Alfredo Falcone	59
16	KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 2009 ·CINECA IRIS Institutial research information system (University of Pisa) ·Annamaria Ruzzo, Fotios Loupakis, Emanuele Canestrari, Chiara Cremolini, Bruno Vincenzi, Lisa Salvatore, Daniele Santini, Gianluca Masi, I. Stasi, Eliana Rulli, Irene Floriani, Katia Bencardino, Nadia Galluccio, S D'Emidio, Vincenzo Catalano, Giuseppe Tonini, Mauro Magnani, Alfredo Falcone, Francesco Graziano	2
17	6081 Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II G.O.N.O. trial 2009 ·European Journal of Cancer Supplements ·Gianluca Masi, Lisa Salvatore, Lorenzo Fornaro, Enrico Vasile, Giacomo Giulio Baldi, I. Stasi, A. Ciarlo, Alessandro Tuzi, M. Andreuccetti, Alfredo Falcone	2
18	Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment 2008 ·European Journal of Cancer Supplements ·I. Stasi, Fotios Loupakis, (unknown), Gianluca Masi, Niccola Funel, Mario Scartozzi, Iacopo Petrini, Daniele Santini, Stefano Cascinu, Alfredo Falcone	1
19	First-line treatment of metastatic colorectal cancer (MCRC) with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the G.O.N.O. Group 2008 ·CINECA IRIS Institutial research information system (University of Pisa) ·Gianluca Masi, Fotios Loupakis, Giacomo Giulio Baldi, Lorenzo Fornaro, I. Stasi, Enrico Vasile, A. Ciarlo, (unknown), Angelo Di Leo, M. Puglisi, Marika Ciprotti, D. Amoroso, Elena Fea, Samantha Di Donato, Alfredo Falcone	2
20	Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroderma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients 2006 ·Journal of Clinical Oncology ·Enrico Vasile, Elisa Giovannetti, Carmelo Tibaldi, Valentina Mey, Sara Nannizzi, Lorenza Landi, I. Stasi, Romano Danesi, Mario Del Tacca, Alfredo Falcone	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact